Omeros Corp's stock surged by 81.37%, reaching a 52-week high, as the company announced significant news regarding its drug YARTEMLEA.
The surge is attributed to Omeros receiving FDA approval for YARTEMLEA, the first effective therapy for transplant-associated thrombotic microangiopathy (TA-TMA). This approval addresses a critical gap in care for this high-risk condition, with clinical trial results showing a complete response rate of 61% in a pivotal Phase 2 trial. The favorable benefit-risk profile of the drug further supports its clinical application, paving the way for its launch in the U.S. in January 2026.
This FDA approval not only enhances Omeros' market position but also reflects the company's commitment to addressing unmet medical needs. The anticipated launch and potential expansion into global markets could significantly impact the company's growth trajectory.
Wall Street analysts forecast OMER stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast OMER stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 13.450
Low
6.22
Averages
13.11
High
20.00
Current: 13.450
Low
6.22
Averages
13.11
High
20.00
H.C. Wainwright
Brandon Folkes
maintain
$20 -> $40
2026-01-08
New
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $40
2026-01-08
New
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-12-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-12-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.
H.C. Wainwright
Brandon Folkes
Buy
maintain
$9
2025-06-27
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$9
2025-06-27
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes keeps a Buy rating on Omeros with a $9 price target after the company submitted its marketing authorization to the European Medicines Agency for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The announcement supports H.C. Wainwright's view that Omeros shares "may be entering a phase of rerating" over the next 12 months, driven by a potential U.S. approval for narsoplimab, EU approval, and subsequent re-appreciation of the potential in the company's other pipeline programs, the analyst tells investors in a research note. The firm believes the European submission adds another "significant catalyst" for the stock in 2026. H.C. Wainwright says narsoplimab will be approved in the U.S. and Europe, and will create significant value for Omeros.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$36
2025-04-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$36
2025-04-11
Maintains
Strong Buy
Reason
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
